297 related articles for article (PubMed ID: 17055622)
21. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
[TBL] [Abstract][Full Text] [Related]
22. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
Chowdhury MI; Sheikh A; Qadri F
Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759
[TBL] [Abstract][Full Text] [Related]
23. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
[TBL] [Abstract][Full Text] [Related]
24. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.
Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF
Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948
[TBL] [Abstract][Full Text] [Related]
25. Comparison of O-specific polysaccharide responses in patients following infection with
Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
[TBL] [Abstract][Full Text] [Related]
27. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
[TBL] [Abstract][Full Text] [Related]
29. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
[TBL] [Abstract][Full Text] [Related]
30. [Cholera vaccine].
Ehara M
Nihon Rinsho; 2005 May; 63 Suppl 5():625-30. PubMed ID: 15954420
[No Abstract] [Full Text] [Related]
31. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
Jertborn M; Svennerholm AM; Holmgren J
Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
[TBL] [Abstract][Full Text] [Related]
32. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
33. Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
Im J; Islam MT; Ahmmed F; Kim DR; Chon Y; Zaman K; Khan AI; Ali M; Marks F; Qadri F; Clemens JD
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007179. PubMed ID: 30870416
[TBL] [Abstract][Full Text] [Related]
34. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.
Qadri F; Wierzba TF; Ali M; Chowdhury F; Khan AI; Saha A; Khan IA; Asaduzzaman M; Akter A; Khan A; Begum YA; Bhuiyan TR; Khanam F; Chowdhury MI; Islam T; Chowdhury AI; Rahman A; Siddique SA; You YA; Kim DR; Siddik AU; Saha NC; Kabir A; Cravioto A; Desai SN; Singh AP; Clemens JD
N Engl J Med; 2016 May; 374(18):1723-32. PubMed ID: 27144848
[TBL] [Abstract][Full Text] [Related]
36. Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4.
Thiem VD; Canh DG; Anh DD; Deen JL; von Seidlein L; Clemens JD; Holmgren J
Vaccine; 2007 Nov; 25(47):7981-3. PubMed ID: 17933443
[No Abstract] [Full Text] [Related]
37. Immune responses to cholera in children.
Leung DT; Chowdhury F; Calderwood SB; Qadri F; Ryan ET
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):435-44. PubMed ID: 22512753
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
[TBL] [Abstract][Full Text] [Related]
39. Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings.
Desai SN; Akalu Z; Teferi M; Manna B; Teshome S; Park JY; Yang JS; Kim DR; Kanungo S; Digilio L
Trop Med Int Health; 2016 Feb; 21(2):194-201. PubMed ID: 26681205
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India.
Kanungo S; Sen B; Ramamurthy T; Sur D; Manna B; Pazhani GP; Chowdhury G; Jhunjhunwala P; Nandy RK; Koley H; Bhattacharya MK; Gupta S; Goel G; Dey B; M T; Nair GB; Ghosh A; Mahalanabis D
PLoS One; 2014; 9(7):e99381. PubMed ID: 24983989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
